ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2009

Oct 13, 2009

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARROWHEAD RESEARCH CORP (ARWR)
CIK: 0000879407
Period of Report: 2009-10-08

Reporting Person: Anzalone Christopher Richard (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2009-10-08	Stock Option	$0.51	A	1126500	Acquired	2019-10-08	Common Stock (1126500)	Direct

Footnotes

F1: 11% of the option award would be vested at the time of the grant and the remaining 89% would vest ratably on a quarterly basis over the next two years.